A researcher in a lab looking at a tablet.

Tag: research

  • blue circle with "ALKtALK by ALK+ Positive."

    Live from ASCO with Break Through Cancer

    🚨 LIVE from ASCO – You’re Invited! 🚨 We’re kicking off ALK Positive Awareness Month 2025 with a special ALKtALK, featuring a research update from Break Through Cancer and a look at what’s ahead. 🎙 Featuring: Jesse Boehm, PhD📅 Sunday, June 1🕖 7:00 PM ET📍 Streaming on Zoom This year’s Powered by Patients campaign is…

    Read More

  • blue circle with "ALKtALK by ALK+ Positive."


    Let’s talk meds, interactions, and whole-person care in thoracic oncology.

    Join ALKtALK for a discussion on Managing Meds & More: The Pharmacist’s Role in ALK+ Cancer

    Read More

  • Normal ALK Function

    What function does ALK serve in a healthy human? Read on for some fascinating proposed hypotheses. We all know that a faulty ALK activation domain leads to all kinds of trouble. But what is the normal function of the ALK protein? ALK was identified in 1997 by two groups, Iwahara et. al. and Morris et…

    Read More

  • The two most surprising risk factors for lung cancer

    Worldwide about 2,100,000 people are diagnosed with lung cancer every year. Approximately 85% of them have used tobacco products. Most are older and in poor health. It’s an insidious disease that few people survive long term.  However, in the last few decades, doctors have noticed a surprising uptick in younger, relatively healthy people with no…

    Read More

  • Lung Cancer Research Awards funded by ALK Positive Inc. in partnership with LUNGevity Foundation

    ALK-positive lung cancer patients continue to fund research relevant to their survival FOR IMMEDIATE RELEASE WASHINGTON, DC (Date, 2020) — Patient group ALK Positive and LUNGevity Foundation today announced the three 2020 recipients of the ALK-positive Lung Cancer Research Awards. This award, driven by ALK Positive–a group that has grown to 2,000+ ALK-positive lung cancer…

    Read More

  • $500,000 Research grant to combat cancer treatment resistance

    SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ — ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 Foundation for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung cancer researchers dedicated to overcoming treatment resistance. This grant funds research to help break down…

    Read More

  • Case Study: successful re-use of Brigatinib after Lorlatinib

    Case study: Successful re-use of Brigatinib after Lorlatinib The patient in this case study was diagnosed with ALK-positive lung cancer in 2005 and had disease progression on several occasions.  Chemotherapy and radiation were used to treat the first two local progressions to the brain and spinal cord.  In 2012, the patient was prescribed Crizotinib for…

    Read More

  • MET and TP 53: How they relate to ALK lung cancer

    MET Amplification MET is a receptor tyrosine kinase that participates in the hepatocyte growth factor (HGF)-mediated signaling pathway.  This protein is anchored to the cell wall to pass information from the outside the cell to the inside of the cell.  Normally, the receptor is activated by binding to HGF.  This binding leads to phosphorylation (adding…

    Read More

  • ALK Positive Inc. partners with GO2 Foundation for groundbreaking ALK Research

    We are excited to partner with the new GO2 Organization. With this new powerhouse partner, we will fund more research, lower our overhead costs, and provide more treatment for this disease. We will launch a new fundraising portal this month. More details are soon to come with full research proposal announcements. FAQ’s   How will the…

    Read More